GSK Gears Up for Q1 Earnings: Here's What to Expect
https://www.zacks.com/stock/news/2260559/gsk-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_article-2260559
Apr 23, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
0
Pages: 1
Page 1